1. An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination
- Author
-
Alfonso Tafur, Eduardo Ramacciotti, Jawed Fareed, Fabio Lievano, Grigoris T. Gerotziafas, Omer Iqbal, Charles A. Carter, Joseph Lewis, Meharvan Singh, Jeanine M. Walenga, Bruce E. Lewis, Walter Jeske, Bulent Kantarcioglu, Loyola University [Chicago], Abbvie Inc. [North Chicago], Service d'Hématologie biologique [CHU Tenon], CHU Tenon [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
Male ,MESH: Models, Cardiovascular ,[SDV]Life Sciences [q-bio] ,thrombocytopenia ,Review ,Platelet Factor 4 ,Pathogenesis ,Sinus Thrombosis, Intracranial ,0302 clinical medicine ,MESH: Genetic Vectors ,MESH: Platelet Factor 4 ,Pandemic ,Global health ,Drug approval ,MESH: Autoantibodies ,MESH: COVID-19 ,030212 general & internal medicine ,Drug Approval ,Glycosaminoglycans ,0303 health sciences ,Clinical Trials as Topic ,Vaccines, Synthetic ,heparin induced thrombocytopenia ,Models, Cardiovascular ,MESH: Glycosaminoglycans ,Hematology ,General Medicine ,3. Good health ,Vaccination ,safety and efficacy ,MESH: Sinus Thrombosis, Intracranial ,MESH: COVID-19 Vaccines ,Female ,Safety ,MESH: Vaccines, Inactivated ,medicine.medical_specialty ,MESH: Pandemics ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,MESH: Clinical Trials as Topic ,MESH: Vaccines, Synthetic ,MESH: Disseminated Intravascular Coagulation ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Genetic Vectors ,Objective assessment ,03 medical and health sciences ,ChAdOx1 nCoV-19 ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Humans ,MESH: SARS-CoV-2 ,MESH: Thrombosis ,Intensive care medicine ,Pandemics ,BNT162 Vaccine ,thrombosis ,030304 developmental biology ,Autoantibodies ,MESH: Humans ,Ad26COVS1 ,business.industry ,MESH: Drug Approval ,SARS-CoV-2 ,MESH: Safety ,COVID-19 ,Disseminated Intravascular Coagulation ,MESH: Male ,Vaccines, Inactivated ,RC666-701 ,business ,MESH: Female - Abstract
International audience; Today the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global health problem. After more than a year with the pandemic, although our knowledge has progressed on COVID-19, there are still many unknowns in virological, pathophysiological and immunological aspects. It is obvious that the most efficient solution to end this pandemic are safe and efficient vaccines. This manuscript summarizes the pathophysiological and thrombotic features of COVID-19 and the safety and efficacy of currently approved COVID-19 vaccines with an aim to clarify the recent concerns of thromboembolic events after COVID-19 vaccination. The influx of newer information is rapid, requiring periodic updates and objective assessment of the data on the pathogenesis of COVID-19 variants and the safety and efficacy of currently available vaccines.
- Published
- 2021